OncoMatch/Clinical Trials/NCT05150691
A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
Is NCT05150691 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments including DB-1303/BNT323 and Pertuzumab for her2-positive advanced solid tumor.
Treatment: DB-1303/BNT323 · Pertuzumab · Ritonavir · Itraconazole — This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1303/BNT323 in subjects with advanced solid tumors that express HER2.
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Biomarker criteria
Required: HER2 (ERBB2) overexpression
HER2-positive or HER2-expressing (except for cohort 2h where the requirement is HER2-null)
Performance status
ECOG 0–1(Restricted strenuous activity)
Lab requirements
Blood counts
adequate organ functions
Kidney function
adequate organ functions
Liver function
adequate organ functions
Cardiac function
LVEF ≥ 50% by ECHO or MUGA; no history of symptomatic CHF (NYHA II-IV) or serious cardiac arrhythmia requiring treatment; no history of myocardial infarction or unstable angina within 6 months before Day 1; average QTcF > 450 ms in males and > 470 ms in females excluded
LVEF ≥ 50% by ECHO or MUGA; adequate organ functions; history of symptomatic CHF (NYHA II-IV) or serious cardiac arrhythmia requiring treatment [excluded]; history of myocardial infarction or unstable angina within 6 months before Day 1 [excluded]; average QTcF > 450 ms in males and > 470 ms in females [excluded]
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Helios Clinical Research · Cerritos, California
- California Research Institute · Los Angeles, California
- Sharp Memorial Hospital · San Diego, California
- Washington Cancer Institute at MedStar Washington Hospital Center · Washington D.C., District of Columbia
- Advanced Research LLC · Coral Springs, Florida
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify